FMP
Enanta Pharmaceuticals, Inc.
ENTA
NASDAQ
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. Enanta Pharmaceuticals, Inc. was founded in 1995 and is headquartered in Watertown, Massachusetts.
6.65 USD
-0.18 (-2.71%)
Free Cash Flow
Year
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
Revenue
122.47M
97.07M
86.16M
79.2M
67.64M
58.39M
50.41M
43.52M
37.58M
32.44M
Revenue %
-
-20.74
-11.24
-8.07
-14.61
-13.67
-13.67
-13.67
-13.67
Operating Cash Flow
7.09M
-70M
-84.78M
-103.15M
-78.76M
-42.59M
-36.77M
-31.75M
-27.41M
-23.66M
Operating Cash Flow %
5.79
-72.11
-98.4
-130.24
-116.45
-72.94
-72.94
-72.94
-72.94
Cap Ex
-1.45M
-750k
-2.13M
-9.06M
-17.95M
-4.95M
-4.27M
-3.69M
-3.19M
-2.75M
Cap Ex %
-1.18
-0.77
-2.47
-11.44
-26.54
-8.48
-8.48
-8.48
-8.48
Free Cash Flow
5.64M
-70.75M
-86.91M
-112.21M
-96.71M
-47.54M
-41.05M
-35.44M
-30.6M
-26.41M
Weighted Average Cost Of Capital
Price
6.65
Beta
Diluted Shares Outstanding
21.16M
Costof Debt
19.72
Tax Rate
After Tax Cost Of Debt
19.43
Risk Free Rate
Market Risk Premium
Cost Of Equity
Total Debt
55.47M
Total Equity
140.69M
Total Capital
196.16M
Debt Weighting
28.28
Equity Weighting
71.72
Wacc
9.82
Build Up Free Cash Flow
Year
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
Revenue
122.47M
97.07M
86.16M
79.2M
67.64M
58.39M
50.41M
43.52M
37.58M
32.44M
Operating Cash Flow
7.09M
-70M
-84.78M
-103.15M
-78.76M
-42.59M
-36.77M
-31.75M
-27.41M
-23.66M
Cap Ex
-1.45M
-750k
-2.13M
-9.06M
-17.95M
-4.95M
-4.27M
-3.69M
-3.19M
-2.75M
Free Cash Flow
5.64M
-70.75M
-86.91M
-112.21M
-96.71M
-47.54M
-41.05M
-35.44M
-30.6M
-26.41M
Wacc
9.82
9.82
9.82
9.82
9.82
Pv Lfcf
-43.29M
-34.03M
-26.75M
-21.03M
-16.53M
Sum Pv Lfcf
-141.65M
Terminal Value
Growth In Perpetuity Method
Long Term Growth Rate
Wacc
9.82
Free Cash Flow T1
-26.94M
Terminal Value
-344.44M
Present Terminal Value
-215.61M
Intrinsic Value
Enterprise Value
-357.26M
Net Debt
18.23M
Equity Value
-375.49M
Diluted Shares Outstanding
21.16M
Equity Value Per Share
-17.75
Projected DCF
-17.75 1.375%
